Influenza immunisation

2 trials MedDRA PT
2 Registered trials
0 Recruiting
2 Unique sponsors
3 Unique IMPs
1 Commercial trials
Drug classes (ATC)
J Anti-infectives (ATC J) 1
— ATC code not specified 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Phase III: 1 Phase IV: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Abbott Biologicals B.V. Commercial
    INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238); INFLUENZA VIRUS A/DARWIN/9/2021 SAN-010 (H3N2), INFLUENZA VIRUS B/MICHIGAN/01/2021, INFLUENZA A/VICTORIA/4897/2022 IVR-238 (H1N1), INACTIVATED; INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), INFLUENZA A VIRUS/THAILAND/8/2022 (H3N2)-LIKE STRAIN (A/CALIFORNIA/122/2022, SAN-022), INACTIVATED
    2024-519743-15-00 5 countries 2025 n=1,193
    Ended

Phase IV

1 trial
  • Finnish Institute For Health And Welfare Academic
    IMP not specified
    2024-515372-12-00 1 country n=1,500
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Abbott Biologicals B.V. Commercial 1 Phase III 0
Finnish Institute For Health And Welfare Academic 1 Phase IV 0
New trials by year
2025
1
← All indication landscapes